Yibing Lu

机构：Second Affiliated Hospital of Nanjing Medical University, Nanning Normal University, Nanjing Medical University

发表论文 8 篇 · 总被引 181 次 · h-index 3

代表论文

• Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial (2022 · Nature Medicine · 被引 96)
• Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial (2022 · Nature Medicine · 被引 76)
• Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China (2025 · Arthritis & Rheumatology · 被引 6)
• Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial (2025 · Diabetologia · 被引 1)
• Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study (2024 · Current Medical Research and Opinion · 被引 1)
• Effect of Finerenone on CKD Outcomes in Type 2 Diabetes: A Chinese Subgroup Analysis of the FIDELIO-DKD Study (2022 · Journal of the American Society of Nephrology · 被引 1)